SCHW vs URGN · P/E 19, rev $13.55B vs rev $109.8M
Charles Schwab Corp (SCHW) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Charles Schwab Corp (SCHW) is a capital markets company listed on NYSE. It is led by Richard Andrew Wurster C.F.A., CMT.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported SCHW revenue for 2026-06-30 was $13.55B. Net income was $5.28B. SCHW currently screens at market cap $164.37B and trailing P/E 18.8.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
SCHW currently screens at market cap $164.37B and trailing P/E 18.8. URGN currently screens at market cap $1.61B.
Not investment advice. Open the SCHW and URGN stock pages for the full models.
Not investment advice.